AI diagnoses PTSD by analyzing veterans’ voices

Working with SRI International, the California tech lab that gave the world Siri, mental health specialists at NYU Langone have developed an AI-based tool that uses voice analysis to diagnose posttraumatic stress disorder—potentially via telemedicine.

Senior study author Charles Marmar, MD, and co-authors described their work in a study published online April 22 in Depression & Anxiety.

In introducing their findings, the authors pointed out that the usual means of diagnosing PTSD—clinical interviews and self-reporting by patients—are subjective and thus prone to inaccuracy.

They set out to create an algorithmic PTSD classifier that could objectively isolate numerous PTSD markers in everything from choice of words to tone of voice to rhythms of verbalization.  

The team drew from audio recordings of 52 Iraq and Afghanistan war veterans with known PTSD and 77 peers who were free of the condition.

Feeding the recordings into SRI software, they were able to identify more than 40,000 speech-based features for the algorithm to analyze.

Marmar and team found the tool distinguished the PTSD patients from the controls at an accuracy rate of nearly 90%.

In a press release sent by NYU Langone, co-lead author Adam Brown, PsyD, said speech is “an attractive candidate for use in an automated diagnostic system, perhaps as part of a future PTSD smartphone app, because it can be measured cheaply, remotely and nonintrusively.”

Marmar added that, with further validation and fine-tuning, speech analysis algorithms may soon be in use in everyday clinical care for PTSD patients.

The study was supported by a U.S. Army research center that has telemedicine as an area of concentration. 

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.